- Home
- GERN vs TSHA Comparison
GERN vs TSHA Comparison
Compare GERN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- TSHA
- Stock Information
- Founded
- GERN 1990
- TSHA 2019
- Country
- GERN United States
- TSHA United States
- Employees
- GERN N/A
- TSHA N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- TSHA Health Care
- Exchange
- GERN Nasdaq
- TSHA Nasdaq
- Market Cap
- GERN 700.6M
- TSHA 728.4M
- IPO Year
- GERN 1996
- TSHA 2020
- Fundamental
- Price
- GERN $1.46
- TSHA $3.00
- Analyst Decision
- GERN Buy
- TSHA Strong Buy
- Analyst Count
- GERN 8
- TSHA 7
- Target Price
- GERN $3.71
- TSHA $8.71
- AVG Volume (30 Days)
- GERN 12.0M
- TSHA 2.6M
- Earning Date
- GERN 08-06-2025
- TSHA 08-12-2025
- Dividend Yield
- GERN N/A
- TSHA N/A
- EPS Growth
- GERN N/A
- TSHA N/A
- EPS
- GERN N/A
- TSHA N/A
- Revenue
- GERN $164,447,000.00
- TSHA $8,098,000.00
- Revenue This Year
- GERN $159.14
- TSHA N/A
- Revenue Next Year
- GERN $52.76
- TSHA N/A
- P/E Ratio
- GERN N/A
- TSHA N/A
- Revenue Growth
- GERN 11877.20
- TSHA N/A
- 52 Week Low
- GERN $1.09
- TSHA $1.05
- 52 Week High
- GERN $4.83
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- GERN 59.63
- TSHA 63.38
- Support Level
- GERN $1.26
- TSHA $2.76
- Resistance Level
- GERN $1.55
- TSHA $3.05
- Average True Range (ATR)
- GERN 0.09
- TSHA 0.15
- MACD
- GERN 0.02
- TSHA 0.00
- Stochastic Oscillator
- GERN 75.00
- TSHA 75.51
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.